Gabriel Pardo

2.6k total citations
62 papers, 975 citations indexed

About

Gabriel Pardo is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Gabriel Pardo has authored 62 papers receiving a total of 975 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pathology and Forensic Medicine, 18 papers in Neurology and 10 papers in Rheumatology. Recurrent topics in Gabriel Pardo's work include Multiple Sclerosis Research Studies (40 papers), Peripheral Neuropathies and Disorders (11 papers) and Autoimmune and Inflammatory Disorders Research (6 papers). Gabriel Pardo is often cited by papers focused on Multiple Sclerosis Research Studies (40 papers), Peripheral Neuropathies and Disorders (11 papers) and Autoimmune and Inflammatory Disorders Research (6 papers). Gabriel Pardo collaborates with scholars based in United States, Canada and Switzerland. Gabriel Pardo's co-authors include Cecilie Fjeldstad, Michael G. Bemben, David Jones, Debra A. Bemben, James Simsarian, Bettina Stubinski, Joel M. Guthridge, Per Soelberg Sørensen, Rosa A. Tang and О. Л. Барбараш and has published in prestigious journals such as The Journal of Immunology, Neurology and Cell Metabolism.

In The Last Decade

Gabriel Pardo

59 papers receiving 935 citations

Peers

Countries citing papers authored by Gabriel Pardo

Since Specialization

Citations

This map shows the geographic impact of Gabriel Pardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Pardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Pardo more than expected).

Fields of papers citing papers by Gabriel Pardo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Pardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Pardo. The network helps show where Gabriel Pardo may publish in the future.

Co-authorship network of co-authors of Gabriel Pardo

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Pardo. A scholar is included among the top collaborators of Gabriel Pardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Pardo. Gabriel Pardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS 2025 ·Neurology ·João Cerqueira, Achim Berthele, Bruce Cree, Massimo Filippi, Gabriel Pardo, Owen Pearson, Anthony Traboulsee, Tjalf Ziemssen, Timothy Vollmer, Corrado Bernasconi, (unknown), (unknown), Cathy Chognot, Catarina Raposo, Hans‐Martin Schneble, (unknown), (unknown), Eva Havrdová	7
2	Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion 2024 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), Nadja Siebert, Klemens Ruprecht, Gaurav Kumar, Rose M. Ko, (unknown), Joel M. Guthridge, Yang Mao‐Draayer, Patrick Schindler, Maria Hastermann, Gabriel Pardo, Friedemann Paul, Robert C. Axtell	1
3	Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels (P9-6.008) 2024 ·Neurology ·Gabriel Pardo, Ludwig Kappos, Anne H. Cross, Jens Kühle, Xavier Montalbán, (unknown), (unknown), Rebecca Piccolo, (unknown), (unknown), Douglas L. Arnold, Enrique Álvarez, Tjalf Ziemssen	1
4	Ankle dorsiflexion asymmetry and the relationship with walking performance in people with multiple sclerosis 2023 ·Gait & Posture ·(unknown), (unknown), Debra A. Bemben, Christopher D. Black, Daniel J. Larson, Gabriel Pardo, Cecilie Fjeldstad, Rebecca Larson	4
5	Autoantibodies identify primary Sjögren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B 2023 ·Annals of the Rheumatic Diseases ·(unknown), (unknown), Bhuwan Khatri, Constantin Georgescu, (unknown), Christina Lawrence, Astrid Rasmussen, Lida Radfar, R. Hal Scofield, Alan N. Baer, Susan A. Robinson, Erika Darrah, Robert C. Axtell, Gabriel Pardo, Jonathan D. Wren, Kristi A. Koelsch, Joel M. Guthridge, Judith A. James, Christopher J. Lessard, A. Darise Farris	10
6	Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis 2022 ·Neurology and Therapy ·Gabriel Pardo, (unknown), Carmen D. Ng, (unknown), Daniel Sheinson, Nicole Bonine	9
7	Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives 2022 ·Journal of Neurology ·(unknown), Bianca Weinstock‐Guttman, Channa Kolb, Dejan Jakimovski, (unknown), Ralph H. B. Benedict, Svetlana Eckert, (unknown), (unknown), Michael G. Dwyer, (unknown), Niels Bergsland, (unknown), Evanthia Bernitsas, Rana Zabad, Gabriel Pardo, (unknown), (unknown), David Hojnacki, Robert Zivadinov	3
8	Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223 2020 ·Journal of Neurology ·Brian Steingo, Yaser Al Malik, Ann Bass, Regina Berkovich, (unknown), Óscar Fernández, Carolina Ionete, Luca Massacesi, Sven G. Meuth, Dimos D. Mitsikostas, Gabriel Pardo, Renata Simm, Anthony Traboulsee, Zia Choudhry, Nadia Daizadeh, D. A. S. Compston, (unknown)	41
9	Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model 2019 ·Journal of Autoimmunity ·Neelakshi R. Jog, Micah T. McClain, Latisha Heinlen, Timothy Gross, Rheal A. Towner, Joel M. Guthridge, Robert C. Axtell, Gabriel Pardo, John B. Harley, Judith A. James	62
10	Telerehabilitation in Multiple Sclerosis: Results of a Randomized Feasibility and Efficacy Pilot Study 2018 ·International Journal of Telerehabilitation ·(unknown), (unknown), Gabriel Pardo	28
11	Headache and Its Management in Patients With Multiple Sclerosis 2018 ·Current Treatment Options in Neurology ·(unknown), Gabriel Pardo, Meheroz H. Rabadi	24
12	Safety and Tolerability of Opicinumab in Relapsing Multiple Sclerosis: the Phase 2b SYNERGY Trial (P5.369) 2017 ·Neurology ·Peter McCroskery, Krzysztof Selmaj, Óscar Fernández, Luigi Maria Edoardo Grimaldi, Eli Silber, Gabriel Pardo, (unknown), Yiwei Zhang, Lei Xu, Diego Cadavid, Michelle Mellion	10
13	The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations 2017 ·Journal of Neurology ·Gabriel Pardo, David Jones	74
14	Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis 2014 ·International Journal of MS Care ·(unknown), Angela Applebee, François Béthoux, Myla Goldman, George J. Hutton, Michele Mass, Gabriel Pardo, (unknown), Herbert R. Henney, Andrew R. Blight, Enrique Carrazana	14
15	Association of vitamin D deficiency with RNFL thickness in MS individuals without history of optic neuritis 2014 ·Multiple Sclerosis and Related Disorders ·Cecilie Fjeldstad, Anette S. Fjeldstad, Joseph P. Weir, Gabriel Pardo	5
16	Changes in Gait, Walking, and Balance Parameters after Withdrawal and Re-Initiation of Dalfampridine Extended Release Tablets in Patients with Multiple Sclerosis: Results from the STEADY Study (P04.103) 2013 ·Neurology ·Cecilie Fjeldstad, Gabriel Pardo, Gustavo Cruz, (unknown), Herbert R. Henney, Adrián L. Rabinowicz	1
17	Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis 2012 ·Multiple Sclerosis and Related Disorders ·B. Singer, Sibyl Wray, Tamara Miller, Mark Cascione, (unknown), Gabriel Pardo, Eric Watsky, Brooke Hayward, (unknown), Fernando Dangond	14
18	Reduced retinal nerve fiber layer and macular thickness in patients with multiple sclerosis with no history of optic neuritis identified by the use of spectral domain high-definition optical coherence tomography 2011 ·Journal of Clinical Neuroscience ·Cecilie Fjeldstad, Michael G. Bemben, Gabriel Pardo	42
19	A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis 2010 ·Journal of Neurology ·Howard Zwibel, Gabriel Pardo, S. Carrie Smith, Douglas R. Denney, MerriKay Oleen-Burkey	26
20	Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis 2007 ·Clinical Therapeutics ·Gavin Giovannoni, О. Л. Барбараш, Florence Casset‐Semanaz, (unknown), John King, Luanne M. Metz, Gabriel Pardo, James Simsarian, Per Soelberg Sørensen, Bettina Stubinski	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact